Cargando…
Exploring the Pathophysiologic Cascade Leading to Osteoclastogenic Activation in Gaucher Disease Monocytes Generated via CRISPR/Cas9 Technology
Gaucher disease (GD) is caused by biallelic pathogenic variants in the acid β-glucosidase gene (GBA1), leading to a deficiency in the β-glucocerebrosidase (GCase) enzyme activity resulting in the intracellular accumulation of sphingolipids. Skeletal alterations are one of the most disabling features...
Autores principales: | Ormazabal, Maximiliano Emanuel, Pavan, Eleonora, Vaena, Emilio, Ferino, Dania, Biasizzo, Jessica, Mucci, Juan Marcos, Serra, Fabrizio, Cifù, Adriana, Scarpa, Maurizio, Rozenfeld, Paula Adriana, Dardis, Andrea Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342917/ https://www.ncbi.nlm.nih.gov/pubmed/37446383 http://dx.doi.org/10.3390/ijms241311204 |
Ejemplares similares
-
CRISPR/Cas9 Editing for Gaucher Disease Modelling
por: Pavan, Eleonora, et al.
Publicado: (2020) -
Bone marrow adipocytes alteration in an in vitro model of Gaucher Disease
por: Crivaro, A., et al.
Publicado: (2023) -
Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease
por: Bondar, Constanza, et al.
Publicado: (2017) -
In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy
por: Ciana, Giovanni, et al.
Publicado: (2020) -
Efficacy of pentosan polysulfate in in vitro models of lysosomal storage disorders: Fabry and Gaucher Disease
por: Crivaro, Andrea N., et al.
Publicado: (2019)